Companies Sionna Therapeutics, Inc.
Sionna Therapeutics (SION): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Email me Sionna Therapeutics, Inc.’s executive pay brief as a PDF
It arrives in about 2 minutes, with every figure cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO pay, last three years
- $3,726,785FY2024
- $6,981,217FY2025
CEO total pay was $6,981,217 in fiscal 2025, up from $3,726,785 in fiscal 2024.
FY2025: salary $646,580 · bonus $0 · stock awards $0 · option awards $5,950,575
Order SION
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.
Executives and directors
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Michael Cloonan | $646,580 | $0 | $0 | $5,950,575 | $374,062 | $0 | $10,000 | $6,981,217 |
| President and Chief Executive Officer | ||||||||
| Caroline Stark Beer | 158,945 | 30,000 | 0 | 5,324,783 | 71,599 | 0 | 7,569 | 5,592,896 |
| Chief Business Officer | ||||||||
| Elena Ridloff | 506,677 | 0 | 0 | 2,085,765 | 254,925 | 0 | 10,000 | 2,857,367 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Michael Cloonan | $6,981,217 | $3,726,785 | — | ↑ +3,254,432 |
| Caroline Stark Beer | 5,592,896 | — | — | — |
| Elena Ridloff | 2,857,367 | 1,300,647 | — | ↑ +1,556,720 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
Our executive compensation program is designed to attract, motivate and retain key employees who best represent our company values and can make significant contributions towards achieving our business purpose. The program is structured to incentivize our executive team based on the achievement of key performance goals, and to align their interests with those of our stockholders, reflecting a pay-for-performance philosophy that supports our business strategy while not encouraging excessive risk-taking.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pearl Meyer & Partners, LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Michael Cloonan | Option | 4,567 | 6.11 | — |
| Michael Cloonan | Option | 13,853 | 6.11 | — |
| Michael Cloonan | Option | 81,985 | 6.11 | — |
| Michael Cloonan | Option | 124,941 | 18 | — |
| Caroline Stark Beer | Option | 255,000 | 28.47 | — |
| Michael Cloonan | Option | 356,450 | 18 | — |
| Michael Cloonan | Option | 369,554 | 6.11 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Joanne Louise Viney, Ph.DIndependent · Compensation (Chair) · Audit · Nominating/Governance · Newly elected | $50,244 | — | $760,072 | — | $0 | $810,316 |
| Marcella Kuhlman Ruddy, M.DIndependent · Nominating and Corporate Governance · Audit · Compensation · Newly elected | 43,494 | — | 760,072 | — | 0 | 803,566 |
| Paul Clancy, M.B.AIndependent · Audit · Nominating and Corporate Governance (Chair) | 83,300 | — | 239,839 | — | 0 | 323,139 |
| Laurie Stelzer, M.B.AIndependent · Audit · Compensation · Nominating/Governance | 59,800 | — | 239,839 | — | 0 | 299,639 |
| H. Edward Fleming Jr., M.DIndependent · Audit · Compensation · Nominating/Governance | 43,200 | — | 239,839 | — | 0 | 283,039 |
| Bruce Booth, D.PhilIndependent | 41,400 | — | 239,839 | — | 0 | 281,239 |
| Peter A. Thompson, M.DIndependent | 40,050 | — | 239,839 | — | 0 | 279,889 |
| Joshua Resnick, M.D., M.B.AIndependent · Compensation | 36,000 | — | 239,839 | — | 0 | 275,839 |
| Lucian Iancovici, M.DIndependent | 0 | 0 | 0 | — | 0 | 0 |
| Michael Cloonan, M.B.AEmployee director · Audit · Compensation · Nominating/Governance | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 16,000 / 12,000 / 9,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $397,488 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $397,488 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Sionna Therapeutics as a peer
Companies that benchmark against SION
No companies currently name SION as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Sionna Therapeutics, Inc. | 2025 | Michael Cloonan | $646,580 | $0 | $5,950,575 | $374,062 | $6,981,217 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
No say-on-pay vote is on file for this company.
CEO pay ratio
| Ratio (CEO : median employee) | — |
|---|---|
| CEO total compensation | — |
| Median employee compensation | — |
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (17 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Michael Cloonan. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 6,981,217. View filing ↗
- Section 01, Caroline Stark Beer. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 5,592,896. View filing ↗
- Section 01, Elena Ridloff. DEF 14A, filed 2026-04-27. Section “Executive Compensation”. As printed: 2,857,367. View filing ↗
- Section 07, pay ratio. 10-K, filed 2026-03-02. Section “CEO Pay Ratio”. As printed: —. View filing ↗
- Section 08, Joanne Louise Viney, Ph.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 810,316. View filing ↗
- Section 08, Marcella Kuhlman Ruddy, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 803,566. View filing ↗
- Section 08, Paul Clancy, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 323,139. View filing ↗
- Section 08, Laurie Stelzer, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 299,639. View filing ↗
- Section 08, H. Edward Fleming Jr., M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 283,039. View filing ↗
- Section 08, Bruce Booth, D.Phil. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 281,239. View filing ↗
- Section 08, Peter A. Thompson, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 279,889. View filing ↗
- Section 08, Joshua Resnick, M.D., M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 275,839. View filing ↗
- Section 08, Lucian Iancovici, M.D. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Michael Cloonan, M.B.A. DEF 14A, filed 2026-04-27. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 397,488 + equity 0 + all other 0 = 397,488, summed across the director compensation table rows.
- Sionna Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-27. CEO total compensation as printed in Sionna Therapeutics, Inc.'s own proxy. As printed: 6,981,217. View filing ↗